Wilmington, DE, United States of America

Paul Joseph Gilligan

This inventor holds 47 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Factor XIa Inhibitors. Top assignees: Bristol-Myers Squibb Compnay, Bristol-Myers Squibb Pharma Company, Dupont Pharmaceuticals Company. Active years: 2000-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul Joseph Gilligan. Retrieved from https://idiyas.com/inventor/paul-joseph-gilligan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 47 (Patent Applications = 2)

% Patents Active = 97.9

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 3.2

ph-index = 13

Forward Citations = 639(Granted Patents)

Location History:

Wilimington, DE (US) (2001)
Wilmington, DE (US) (2000 - 2018)

Company Filing History:

19 out of 3,745

Bristol-Myers Squibb Compnay

patents

14 out of 234

Bristol-Myers Squibb Pharma Company

patents

10 out of 106

Dupont Pharmaceuticals Company

patents

4. 4 out of 15

Dupont Pharmaceuticals, Inc.

patents

Years Active: 2000-2018

Loading Chart...

Areas of Expertise:

Factor XIa Inhibitors

Dihydropyridone

Cyclic P1 Linkers

Arylpropionamide

Corticotropin Releasing Factor

Azolo Triazines

Pyrazolotriazines

Neurological Disorders

Sulfonamide Bicyclic Compounds

Heterocyclic Compounds

Imidazo-pyridines

CNS Disorders

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9951071 - Dihydropyridone P1 as factor XIa inhibitors (2018-04-24),

2. 9902742 - Macrocycles as factor XIa inhibitors (2018-02-27),

3. 9611274 - Macrocycles as factor XIa inhibitors (2017-04-04),

4. 9409908 - Dihydropyridone p1 as factor XIa inhibitors (2016-08-09),

5. 9376444 - Dihydropyridone P1 as factor XIa inhibitors (2016-06-28),

6. 9221818 - Macrocycles as factor XIa inhibitors (2015-12-29),

7. 9108981 - Cyclic P1 linkers as factor XIa inhibitors (2015-08-18),

8. 8901115 - Cyclic P1 linkers as factor XIa inhibitors (2014-12-02),

9. 8604056 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors (2013-12-10),

10. 8367709 - Dipeptide analogs as coagulation factor inhibitors (2013-02-05),

11. 8252830 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors (2012-08-28),

12. 7842708 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors (2010-11-30),

13. 7678793 - Azolo triazines and pyrimidines (2010-03-16),

14. 7662817 - 4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-A]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands (2010-02-16),

15. 7626039 - Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors (2009-12-01),

Title: Paul Joseph Gilligan - Innovative Inventor from Wilmington

Introduction: Paul Joseph Gilligan is a renowned inventor based in Wilmington, Delaware, known for his groundbreaking contributions to various industries.

Latest Patents: Paul Joseph Gilligan holds several patents in the fields of technology, healthcare, and consumer products, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Paul Joseph Gilligan has consistently pushed the boundaries of innovation, leading to the development of cutting-edge solutions that have revolutionized the way we live and work.

Collaborations: Throughout his career, Paul Joseph Gilligan has collaborated with leading companies, research institutions, and universities to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Paul Joseph Gilligan's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor, shaping the future of technology and beyond.

Profile summary based on public USPTO records.